NEW YORK, Jul 07, 2008 (BUSINESS WIRE) ----Pfizer announced today that new statin users who took Lipitor(R) (atorvastatin calcium) were significantly more likely to stay on their medication compared to those who took simvastatin, according to an observational study of more than 186,000 patients in one of the largest U.S. managed care claims databases. The results were published in the July issue of Current Medical Research and Opinion.

"It is important for patients to remain on their medications, especially those with chronic conditions such as high cholesterol, which when uncontrolled may increase a patient's risk for heart attacks and strokes," said Dr. JoAnne M. Foody, study lead author, associate professor of medicine at Harvard Medical School and director of the Cardiovascular Wellness Center at Brigham and Women's/Faulkner Hospitals, Boston. "In patients who take statins to manage their cholesterol levels, poor persistence has been linked with an increase in heart attacks and strokes in addition to higher healthcare costs."

According to the results:

-- Of patients without prior cardiovascular events (n=175,322), those treated with Lipitor were a significant 15 percent less likely to discontinue therapy in the first year than those treated with simvastatin.

-- Of patients who had at least one prior cardiovascular event (n=11,331), those treated with Lipitor were a significant 22 percent less likely to discontinue therapy than those treated with simvastatin.

A subanalysis examined the persistence rates of patients aged 65 years and older, who are at a higher risk for cardiovascular events and are known to have lower persistence rates than younger patients. In this retrospective database analysis, persistence rates were defined as the number of days a patient remained on treatment in the first year following medication start date.

According to the results:

 -- Overall, persistence was worse in elderly patients than in younger patients for both statins,
   but the relative difference between Lipitor and simvastatin users was similar to that of the overall patient population. --
   Elderly patients without prior cardiovascular events (n=8,278) treated with Lipitor were a significant 22 percent less likely
   to discontinue therapy than those treated with simvastatin. -- Elderly patients with at least one prior cardiovascular event
   (n=980) treated with Lipitor were a significant 26 percent less likely to discontinue therapy than those treated with simvastatin.
   

"Today, physicians face increasing pressure to switch from established statin therapy to generics, based on the perception that all statins are equivalent," said Dr. Rochelle Chaiken, vice president of Pfizer's global cardiovascular and metabolic medical team. "This observational study provides important real-world insights into statin usage patterns and suggests that the choice of statin may have a significant effect on whether a patient remains on their prescribed medication. When choosing a medication, it is critical for clinicians to consider all of the factors that may influence the long-term effectiveness of therapy."

About the study

This Pfizer-funded study was a retrospective analysis using anonymous patient-level health plan data from IMS Health, a healthcare information and consulting company. At the time of the analysis, the IMS database included fully adjudicated medical and pharmacy claims for 52 million individual patients from 92 health plans across the U.S. A total of 186,653 primary and secondary prevention patients with at least one complete year of follow up were included in this study; 136,652 patients received atorvastatin, and 50,001 received simvastatin.

As with all observational studies, this study has some limitations. For example, the reasons for medication discontinuation were not tracked in the database. Although the analysis accounted for a range of important variables, differences in persistence after adjusting for all known baseline imbalances could still be due in part to unmeasured confounding factors such as differences in effectiveness, side-effects, cost or other attributes of the statins. Further studies are required to explore these factors.

Important U.S. Prescribing Information

Lipitor is a prescription medication. It is used in patients with multiple risk factors for heart disease such as family history, high blood pressure, age, low HDL ("good" cholesterol) or smoking to reduce the risk of a heart attack and stroke, certain kinds of heart surgery and chest pain.

Lipitor is also used in patients with type 2 diabetes and at least one other risk factor for heart disease such as high blood pressure, smoking or complications of diabetes, including eye disease and protein in urine, to reduce the risk of heart attack and stroke.

Lipitor is used in patients with existing coronary heart disease to reduce the risk of heart attack, stroke, certain kinds of heart surgery, hospitalization for heart failure, and chest pain.

When diet and exercise alone are not enough, Lipitor is used along with a low-fat diet and exercise to lower cholesterol.

Lipitor is not for everyone. It is not for those with liver problems. And it is not for women who are nursing, pregnant or may become pregnant.

Patients taking Lipitor should tell their doctors if they feel any new muscle pain or weakness. This could be a sign of rare but serious muscle side effects. Patients should tell their doctors about all medications they take. This may help avoid serious drug interactions. Doctors should do blood tests to check liver function before and during treatment and may adjust the dose. The most common side effects are gas, constipation, stomach pain and heartburn. They tend to be mild and often go away.

For additional product information, visit www.Lipitor.com.

SOURCE: Pfizer

Pfizer Media: Vanessa Aristide, 212-733-3784 Rebecca Hamm, 212-733-8811 or Investors: Jennifer
   Davis, 212-733-0717 

Copyright Business Wire 2008 **********************************************************************
   As of Thursday, 07-03-2008 23:59, the latest Comtex SmarTrend� Alert, an automated pattern recognition system, indicated a
   DOWNTREND on 01-02-2008 for PFE @ $22.87. For more information on SmarTrend, contact your market data provider or go to www.mysmartrend.com
   SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright � 2004-2008 Comtex News Network, Inc. All rights
   reserved.